JP2006347958A - Antiinflammatory spray for pharyngeal mucosa - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antiinflammatory spray for pharyngeal mucosa, useful for pharyngitis due to cold, especially for pharyngodynia. <P>SOLUTION: The antiinflammatory spray for pharyngeal mucosa, compounded with tranexamic acid and a germicidal disinfectant ingredient, and the antiinflammatory spray for pharyngeal mucosa, compounded with tranexamic acid, a germicidal disinfectant ingredient and, if required, a thickener such as polyvinylpyrrolidone, are provided, wherein the germicidal disinfectant ingredient is one or more selected from a group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, dequalinium chloride, thymol, chlorhexidine gluconate and dialkylaminoethyl glycine. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a pharyngeal mucosa anti-inflammatory spray containing tranexamic acid and a bactericidal antiseptic component, or further containing a thickener such as polyvinylpyrrolidone. More specifically, the present invention relates to a pharyngeal mucosa anti-inflammatory spray useful for throat swelling, throat hyperemia, and particularly sore throat, which is a sore throat caused by a cold.

  Conventionally, as oral mucosal sprays, oral mucosal sprays containing iodine, povidone iodine and cetylpyridinium chloride as disinfecting / disinfecting components, or oral mucosal sprays containing sodium azulenesulfonate as an anti-inflammatory component are commercially available. These sprays are mainly used to treat acute upper respiratory tract inflammation due to colds.

  A cold is an acute inflammatory disease of the respiratory mucosa. The respiratory tract is an organ that extends from the nasal cavity to the pharynx, larynx, trachea, bronchus, and lungs. The cold is an acute inflammation throughout the respiratory tract, or throughout the respiratory tract, that is, a condition in which the mucous membrane swells red. If the nasal mucosa is inflamed, symptoms of nasal inflammation such as sneezing, nasal congestion and nasal congestion will occur. Inflammation of the pharyngeal mucosa will cause pharyngeal inflammation such as swelling of the throat, redness of the throat and sore throat. Similarly, in laryngitis and bronchitis, symptoms such as rattling voices, coughing, and sputum appear. Symptoms from each site, the general symptoms that appear in various degrees are colds, and the symptoms are not limited to the respiratory tract, when the inflammation progresses to a certain degree, systemic reactions, such as fever, headache, back pain, The whole body's dullness also appears.

Acute upper respiratory tract inflammation caused by a cold accounts for most of the cause of the virus, but the acute upper respiratory tract inflammation caused by the virus is said to be recovered in about one week. However, if epithelial cells are destroyed by viral infection, bacteria enter and settle and secondary infection occurs.
Therefore, the basics of cold treatment are coping therapy rather than causal therapy for viruses, and many coping therapy is used to relieve unpleasant symptoms and prevent secondary infection by bacteria. For prevention and treatment of secondary infections caused by this bacterium, oral mucosal sprays containing a sterilizing and disinfecting ingredient are commercially available, and throat disinfection, voice caused by throat inflammation, throat, and throat discomfort Has been applied to which pain, swelling of the throat.

  As a sterilizing and disinfecting component, iodine, povidone iodine and cetylpyridinium chloride are blended in the spray agent. However, iodine and povidone iodine have a taste and smell peculiar to iodine, and there is also a decrease in thyroid function due to iodine hypersensitivity and iodine overdose, so that sprays containing iodine and povidone iodine are restricted in use. There were drawbacks.

  In addition, sprays formulated with sodium azulene sulfonate, an anti-inflammatory component, are used for voice, throat, discomfort, sore throat, swelling of the throat, stomatitis due to inflammation of the oral mucosa. However, although this sodium azulene sulfonate has an effect on mucosal inflammation, it has no bactericidal disinfection action against bacteria, and there was a limit to the treatment of mucosal inflammation due to cold. Therefore, the development of a mucosal anti-inflammatory spray that combines a sterilizing and anti-inflammatory component has been requested. However, a mucosal anti-inflammatory spray for colds that contains both a sterilizing and anti-inflammatory component is required. It was not realized yet.

  In particular, the sore throat caused by a cold is a common symptom in daily life, and it often causes difficulty in swallowing due to severe sore throat and inability to eat. Although it was eagerly desired to relieve sore throat and to be able to eat early, a pharyngeal mucosa anti-inflammatory spray useful for this sore throat has not been realized yet.

  Currently, a liquid preparation for external use containing a quaternary ammonium salt type cationic antibacterial component and an antiplasmin component, tranexamic acid, has been proposed for the prevention and treatment of periodontal diseases, or for cleaning the periphery of the anus and the like. For example, Patent Document 1 discloses a composition for oral cavity such as caries, periodontal disease, bad breath, etc., anti-plasmin component tranexamic acid and / or ε-aminocaproic acid, quaternary ammonium salt type cationic antibacterial component, stevia A composition comprising a sweetener is disclosed.

  Patent Document 2 discloses a composition comprising a quaternary ammonium salt type cationic antibacterial component, an antiplasmin component, and sodium chloride as an oral composition for the prevention and treatment of periodontal diseases. Furthermore, Patent Document 3 similarly discloses a composition comprising a quaternary ammonium salt type cationic antibacterial component, an antiplasmin component, sodium chloride, and magnesium chloride as an oral composition for the prevention and treatment of periodontal diseases. ing. Patent Document 4 describes a composition comprising a combination of a quaternary ammonium salt type cationic antibacterial component and / or an antiplasmin component and maltitol as an oral composition for the prevention and treatment of periodontal diseases. .

Patent Document 5 describes a composition comprising a combination of tranexamic acids, water-soluble bactericidal components (quaternary ammonium salt type cationic antibacterial components and / or chlorhexidine gluconate) as a cleanser for the perianal region and the like. Has been. Patent Document 6 describes a composition comprising a combination of a quaternary ammonium salt type cationic antibacterial component and / or tranexamic acid and water-soluble calcium as an oral composition such as antibacterial and gingivitis.
However, no pharyngeal mucosal anti-inflammatory spray useful for pharyngitis of acute upper respiratory tract inflammation caused by cold, particularly pharyngeal headache, has been reported yet.

Japanese Patent No. 3070152 JP-A-9-95429 JP-A-9-95457 JP 2003-128540 A JP 2005-68076 A JP 2005-104911 A

  An object of the present invention is to provide a pharyngeal mucosal anti-inflammatory spray agent that reduces and removes sore throat, redness of the throat, sore throat, particularly sore throat, which is a sore throat mucositis caused by a cold. Sore throat caused by a cold is a common symptom in daily life, and it often causes difficulty in swallowing due to severe sore throat, and inability to eat. An object of the present invention is to provide a pharyngeal mucosal anti-inflammatory spray that is useful for pharyngitis, particularly pharyngeal headache, in order to alleviate sore throat and enable a meal.

  As a result of intensive research to solve the above-mentioned problems, the present inventors have found that a spray agent in which a disinfecting component is added to tranexamic acid as an anti-inflammatory component, or a spray agent in which polyvinyl pyrrolidone is further added thereto. The present invention was found to be remarkably useful for throat swelling, throat hyperemia, particularly sore throat, which are pharyngeal mucositis, and completed the pharyngeal mucosa anti-inflammatory spray of the present invention.

Therefore, the present invention specifically includes the following configuration.
(1) A pharyngeal mucosa anti-inflammatory spray characterized by containing tranexamic acid and a bactericidal antiseptic component;
(2) The disinfectant component is one or more selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, depotassium chloride, thymol, chlorhexidine gluconate, and dialkylaminoethylglycine as described in (1) above Pharyngeal mucosa anti-inflammatory spray;
(3) The pharyngeal mucosa anti-inflammatory spray according to (1) or (2), further comprising a thickener;
(4) A pharyngeal mucosa anti-inflammatory spray characterized by containing tranexamic acid, a bactericidal antiseptic component and a thickener;
(5) The pharyngeal mucosa anti-inflammatory spray according to (3) or (4) above, wherein the thickener is polyvinylpyrrolidone;
It is.

  The pharyngeal mucosal anti-inflammatory spray containing tranexamic acid provided in the present invention with a bactericidal antiseptic component or further containing a thickening agent such as polyvinylpyrrolidone is a sore throat, throat swelling caused by a cold. Hyperemia, especially sore throat, is remarkably improved. In addition, the pharyngeal mucosal anti-inflammatory spray provided by the present invention reduces the sore throat, i.e. sore throat, which is a common symptom of common cold, at an early stage and makes it difficult to eat food due to dysphagia. Therefore, it is extremely useful as a therapeutic agent for pharyngitis due to colds, particularly for sore throat.

As described above, the basis of the present invention is a spray agent in which a disinfectant component is blended with tranexamic acid as an anti-inflammatory component, and further a spray agent in which an antibacterial agent such as polyvinylpyrrolidone is blended.
The basis of cold treatment is, as described above, rather than causal therapy for viruses, rather than relieving unpleasant symptoms and coping therapy for preventing secondary infection by bacteria.
Tranexamic acid used in the present invention has a chemical name of trans-4- (aminomethyl) cyclohexanecarboxylic acid and is known to have an antiplasmin action. This plasmin inhibitory action causes hemostasis and antiallergy. Anti-inflammatory effects such as are recognized.

Up to now, tranexamic acid has been used as a pharmaceutical in the form of injection or oral administration (capsule, tablet, powder, syrup), but its use as an external preparation, especially as a pharyngeal mucosa anti-inflammatory spray, has been reported. Not.
Therefore, it can be said that the present invention is very specific in this respect.

Hereinafter, the specificity of the present invention will be described in more detail. Pharyngitis due to bacterial infection is caused by streptokinase, staphylococcus, staphylococcus aureus, Staphylococcus aureus, pneumococcus and the like. It is said to be pharyngitis due to the activation of proteolytic enzymes such as phylokinase.
Tranexamic acid used in the present invention brings about anti-inflammatory effects such as hemostasis and anti-vascular permeability by suppressing proteolytic enzymes produced by causative bacteria and plasmin activated by proteolytic enzymes. Is.

  However, tranexamic acid does not inherently have a bactericidal and disinfecting action against pathogenic bacteria. Therefore, in the present invention, a pharyngitis is a pharyngeal mucosal anti-inflammatory spray that disinfects and kills pathogenic bacteria in addition to anti-inflammatory action by adding a disinfectant component in addition to tranexamic acid that is an anti-inflammatory component. It was found that the swelling of the throat, redness of the throat, especially the sore throat, was remarkably improved.

  Hereinafter, the pharyngeal mucosa anti-inflammatory spray of the present invention (hereinafter referred to as spray) will be described more specifically.

  The amount of tranexamic acid to be blended in the spray of the present invention is 0.05 to 10 w / v%, preferably 0.5 to 10 w / v%, more preferably 1 to 7 w / v%. If it is less than 0.05 w / v%, the intended anti-inflammatory action cannot be exerted, and even if it exceeds 10 w / v%, no further effect can be expected and it is useless.

On the other hand, examples of the sterilizing and disinfecting component to be blended with tranexamic acid include cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, depotassium chloride, thymol, chlorhexidine gluconate, and dialkylaminoethylglycine. Particularly preferred is cetylpyridinium chloride.
In the present invention, one or more of these sterilizing and disinfecting components can be used.
In the spray agent of the present invention, the blending amount of the sterilizing and disinfecting component is 0.01 to 1 w / v%, more preferably 0.1 to 0.5 w / v%. If it is less than 0.01 w / v%, the intended sterilizing and disinfecting effect cannot be exerted, and even if it exceeds 1 w / v%, no further effect is recognized, but rather a waste of resources. It becomes.

  In the spray agent of the present invention, polyvinylpyrrolidone blended in addition to the above tranexamic acid and the sterilizing and disinfecting component is also known as povidone, and is divided according to the degree of polymerization, and is K17 (molecular weight 10,000), K25 (molecular weight). 40,000), K30 (molecular weight 40,000), K90 (molecular weight 360,000), etc., any of which can be used.

These polyvinylpyrrolidones are added to the pharyngeal mucosa anti-inflammatory spray of the present invention to increase the viscosity of the drug solution, and by spraying this solution on the affected part of the pharynx, a film of the drug solution is formed. The medicinal component can be retained for a long time.
The compounding quantity of polyvinylpyrrolidone in this case is 0.05 to 10 w / v%, preferably 0.5 to 10 w / v%, more preferably 1 to 7 w / v%.
If it is less than 0.05 w / v%, the intended effect cannot be increased, and even if it exceeds 10 w / v%, no further effect is recognized.

  In addition to the above components, the spray agent provided by the present invention further contains a polyhydric alcohol, sugar alcohol, refreshing agent, corrigent, sweetener, surfactant, thickener, stabilizer, preservative, etc. Can be appropriately blended.

  Examples of the polyhydric alcohol include glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, and polyethylene glycol. Among these, glycerin and propylene glycol are preferable. One or more of these polyhydric alcohols can be used in combination.

  Examples of the sugar alcohol include sorbitol, xylitol, mannitol, erythritol, maltitol, maltose, xylose and the like. In particular, sorbitol and xylitol are preferable. One or more of these sugar alcohols can be used in combination. The blending amount of the polyhydric alcohol and the sugar alcohol is not particularly limited, but is usually 1 to 70 w / v%, preferably 5 to 70 w / v%.

  Refreshing agents include menthol, eucalyptus oil, clove oil, carvone, eugenol, linalool, cinerol, anethole, peppermint oil, lemon oil, spearmint oil, peppermint oil, fennel oil, camphor, borneol, natural mint, sage, rosemary , Thyme, basil, chamomile and the like. Preferable examples include menthol, eucalyptus oil, and lemon oil. The compounding quantity of a refreshing agent is 0.005-0.2 w / v%.

  Examples of the corrigent include saccharin sodium, ethanol, aspartame, licorice extract, dextrin and the like.

  Examples of the sweetener include sucrose, honey, powdered reduced maltose starch syrup, fructose, glucose and the like. The blending amount is not particularly limited, and an appropriate amount can be blended if desired.

  Examples of the surfactant include nonionic surfactants and ionic surfactants.

  Examples of the nonionic surfactant include polyoxyethylene sorbitan fatty acid ester: for example, polysorbate 60, polysorbate 80, etc., polyoxyethylene hydrogenated castor oil: for example, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) Hardened castor oil, etc. Polyoxyethylene alkyl ethers: for example, polyoxyethylene (9) lauryl ether, polyoxyethylene (23) cetyl ether, etc. Polyethylene glycol fatty acid esters: eg, polyethylene glycol monostearate (40E.O.) And sucrose fatty acid esters.

  Moreover, sodium lauryl sulfate, sodium lauroyl sarcosine, etc. can be mix | blended as an ionic surfactant.

  These surfactants can be blended in appropriate amounts as desired.

  Examples of the thickener include carmellose sodium, polyvinyl pyrrolidone, polyvinyl alcohol, methyl cellulose, carboxyvinyl polymer, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, pectin, gelatin and the like. Preferred are hydroxypropylmethylcellulose and polyvinylpyrrolidone, and particularly preferred is polyvinylpyrrolidone.

  Examples of the stabilizer include sodium edetate, dibutylhydroxytoluene, sodium bisulfite and the like.

  Examples of the preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, sorbic acid, sodium benzoate and the like.

  Examples of the pH adjuster include citric acid, sodium citrate, malic acid, tartaric acid, hydrochloric acid, phosphoric acid, sodium hydroxide, sodium hydrogen carbonate, sodium hydrogen phosphate and the like.

  Further components that can be blended include purified water, sodium chloride, potassium chloride, magnesium chloride and the like.

The spray agent provided by the present invention dissolves the ingredients appropriately in purified water, adjusts the pH and the like as appropriate, and then measures up to a desired dose. The resulting spray solution for the pharyngeal mucosa is placed in a predetermined container. It can be manufactured by filling.
The predetermined container means a normal spray container.

  The present invention will be described in more detail below with reference to examples and test examples, but the present invention is not limited to these examples.

Example 1:
In 60 mL of purified water, 0.5 g of tranexamic acid, 0.1 g of cetylpyridinium chloride and 13 g of sorbitol are dissolved, and a solution prepared by dissolving 0.02 g of menthol and 0.005 g of eucalyptus oil in 8 g of propylene glycol and 10 g of glycerin is added and mixed. To do. The pH was adjusted to 5.75 with citric acid, the volume was made up to 100 mL with purified water, and the resulting spray solution for pharyngeal mucosa was filled into a predetermined container.

Examples 2-4:
It processed similarly to above-mentioned Example 1, the spray liquid for pharyngeal mucosa of Examples 2-4 of following Table 1 was prepared, and the predetermined container was filled.
In addition, the compounding quantity of each component in a table | surface is displayed in g unit.

Example 5:
In 60 mL of purified water, 5 g of tranexamic acid, 0.1 g of benzethonium chloride, and 13 g of sorbitol are dissolved, and a solution prepared by dissolving 0.02 g of menthol and 0.005 g of eucalyptus oil in 8 g of propylene glycol and 10 g of glycerin is added and mixed. Adjust the pH to 5.80 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 6:
Dissolve 5 g of tranexamic acid, 0.1 g of benzalkonium chloride and 13 g of sorbitol in 60 mL of purified water, and add and mix in advance a solution of 0.02 g of menthol and 0.005 g of eucalyptus oil in 10 g of propylene glycol and 10 g of glycerin. . Adjust the pH to 5.84 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 7:
10 g of tranexamic acid, 0.1 g of cetylpyridinium chloride and 2 g of sorbitol are dissolved in 80 mL of purified water, and a solution prepared by dissolving 0.02 g of menthol and 0.005 g of eucalyptus oil in 5 g of propylene glycol is added and mixed. Adjust the pH to 6.00 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 8:
In 60 mL of purified water, 5 g of tranexamic acid, 0.1 g of depotassium chloride and 13 g of sorbitol are dissolved, and a solution prepared by dissolving 0.02 g of menthol and 0.005 g of eucalyptus oil in 8 g of propylene glycol and 10 g of glycerin is added and mixed. Adjust the pH to 5.90 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for the pharyngeal mucosa.

Example 9:
5 g of tranexamic acid and 13 g of sorbitol are dissolved in 60 mL of purified water, and a solution prepared by dissolving 0.02 g of menthol, 0.005 g of eucalyptus oil, and 0.1 g of thymol in 8 g of propylene glycol and 10 g of glycerin is added and mixed. Adjust the pH to 5.85 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for the pharyngeal mucosa.

Example 10:
5 g of tranexamic acid, 0.1 g of chlorhexidine gluconate and 13 g of sorbitol are dissolved in 60 mL of purified water, and a solution prepared by dissolving 0.02 g of menthol and 0.005 g of eucalyptus oil in 8 g of propylene glycol and 10 g of glycerin is added and mixed. Adjust to pH 5.87 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 11:
Dissolve 5 g of tranexamic acid, 0.1 g of dialkylaminoethylglycine and 13 g of sorbitol in 60 mL of purified water, and add and mix in advance a solution of 8 g of propylene glycol and 0.02 g of menthol and 0.005 g of eucalyptus oil in 10 g of glycerin. . Adjust to pH 5.87 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 12:
In 40 mL of purified water, 5 g of tranexamic acid, 0.3 g of cetylpyridinium chloride, 2.5 g of sorbitol, 7.5 g of powdered reduced maltose starch syrup, 0.4 g of sodium hydrogenphosphate, 4 g of polyvinylpyrrolidone (K30) are dissolved in advance. A solution prepared by dissolving 0.08 g of menthol, 0.005 g of eucalyptus oil, and 0.06 g of lemon oil in 8 g and 45 g of glycerin is added and mixed. Adjust the pH to 7.00 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 13:
In 40 mL of purified water, 5 g of tranexamic acid, 0.3 g of cetylpyridinium chloride, 10 g of xylitol, 0.4 g of sodium hydrogenphosphate and 4 g of polyvinylpyrrolidone (K30) are dissolved in advance, 0.08 g of menthol in 8 g of propylene glycol and 45 g of glycerin, A solution in which 0.005 g of eucalyptus oil and 0.06 g of lemon oil are dissolved is added and mixed. Adjust the pH to 7.00 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Example 14:
Dissolve 5 g of tranexamic acid, 0.3 g of cetylpyridinium chloride, 10 g of xylitol, 0.4 g of sodium hydrogenphosphate and 4 g of polyvinylpyrrolidone (K30) in 40 mL of purified water, and in advance 0.08 g of menthol and 0 eucalyptus oil in 50 g of glycerin. Add a solution of 0.005 g and 0.06 g of lemon oil and mix. Adjust the pH to 7.00 with citric acid, make up to 100 mL with purified water, and fill the resulting container with the resulting spray solution for pharyngeal mucosa.

Stability test:
About the chemical | medical solution of Example 1- Example 4 obtained above, a severe test (heating: 60 degreeC x 2 weeks, exposure: 600,000 lux time) was implemented.
The results are shown in Table 2 below. As can be seen from the results shown in the table, in storage under severe conditions, the spray of the present invention has almost no change in the content of tranexamic acid contained in the spray liquid or the pH of the chemical liquid, It was stable.

Antipharyngitis test:
Ten panelists complaining of sore throats at various stages of sore throat caused by a cold used the pharyngeal mucosa anti-inflammatory spray of Example 13 for at least 5 days.
For each paneler, the symptoms of cold at the start of the antipharyngitis test and subjective symptoms such as swelling of the throat, redness of the throat, sore throat and severe throat pain after 5 days of use were improved. The presence or absence was quantified and the effect of the pharyngeal mucosa anti-inflammatory spray was evaluated.
In addition, the evaluation judgment confirmed the pharyngeal symptom with the naked eye, the subjective symptom, etc., and evaluated it by marked improvement>improvement> improvement.
The results are shown in Table 3 below.

As can be seen from the above results, the sore throat in 10 panelists improved to subjective symptoms such as swollen throat, redness in the throat, sore throat, severe throat pain, and difficulty swallowing. Further improvement and marked improvement were observed, and it was found that the pharyngeal mucosa anti-inflammatory spray of the present invention is useful for sore throat.
Especially for panelists with moderate sore throat, subjective symptoms such as swollen throat, redness in the throat, sore throat, and sore throat, which are difficult to swallow due to severe pain in the throat, can be remarkably improved after 5 days. It was.

  Therefore, the pharyngeal mucosal anti-inflammatory spray containing the tranexamic acid and the disinfecting and disinfecting component of the present invention, or further containing polyvinylpyrrolidone improves the pharyngitis caused by the cold, and its usefulness has been confirmed. .

As described above, the present invention is a pharyngeal mucosal anti-inflammatory spray comprising a tranexamic acid having an anti-inflammatory action and a sterilizing and disinfecting component, or further a thickener such as polyvinylpyrrolidone. It remarkably improves sore throat swelling, redness of the throat, especially sore throat. In addition, the pharyngeal mucosal anti-inflammatory spray provided by the present invention reduces the sore throat, i.e. sore throat, which is a common symptom of common cold, at an early stage and makes it difficult to eat food due to dysphagia. Therefore, it is extremely useful as a therapeutic agent for the treatment of sore throat caused by a cold, particularly a sore throat, and its medical value is great.

Claims (5)

  A pharyngeal mucosa anti-inflammatory spray characterized by containing tranexamic acid and a disinfectant.   2. The pharyngeal mucosa anti-inflammatory according to claim 1, wherein the disinfecting component is at least one selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, depotassium chloride, thymol, chlorhexidine gluconate, and dialkylaminoethylglycine. Spray agent.   Furthermore, the thickener was mix | blended, The pharyngeal mucosa anti-inflammatory spray agent of Claim 1 or 2 characterized by the above-mentioned. A pharyngeal mucosa anti-inflammatory spray comprising tranexamic acid, a bactericidal disinfectant and a thickener. The pharyngeal mucosa anti-inflammatory spray according to claim 3 or 4, wherein the thickener is polyvinylpyrrolidone.